Perrigo confirms first to file patent challenge for generic Aveed®
Perrigo announced it has filed with the FDA an aNDA for testosterone undecanoate injection and that it has notified the owner of the Drug of its filing. Aveed® (testosterone undecanoate) injection is a schedule II controlled substance indicated for testosterone replacement therapy in adult males November 24, 2014